Navigation Links
Misonix Reports First Quarter Fiscal 2010 Financial Results
Date:11/16/2009

FARMINGDALE, N.Y., Nov. 16 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today reported the financial results for the first fiscal quarter 2010 ending September 30, 2009. Michael A. McManus, Jr., President and Chief Executive Officer, and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call Monday, November 16, 2009 at 4:30pm to discuss the Company's first fiscal quarter financial results.

The Company also reported the following financial and operational achievements:

  • On August 5, 2009, we closed the transaction for the sale of our Labcaire Systems Ltd. subsidiary ("Labcaire") to PuriCore International, Limited for up to $5.6 million.
  • On October 2, 2009, we closed a transaction for the sale of substantially all of the assets of Sonora to Medical Imaging Holdings, Inc. for a cash payment of $8 million which is reported as assets held for sale on the Company's Consolidated Balance Sheets as of September 30, 2009.

First Quarter Fiscal 2010 vs. First Quarter Fiscal 2009 Financial Results

Revenue was $2.7 million, a decrease of $.4 million compared to $3.1 million for the first quarter of 2009. The decrease in revenue for the first quarter of 2010 was due to a decrease of $.4 million in medical device products sales to $2.1 million. Reduced sales of the Company's Lysonix(TM) Ultrasonic Assisted Liposuction, SonaStar® Ultrasonic Surgical Aspirator and Autosonix® Cutting and Coagulating System were partially offset by an increase in sales of the SonicOne® Wound Debridement System and Bone Scalpel(TM).

Net loss from continuing operations for
'/>"/>

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
6. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
7. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
8. Misonix Announces New Distribution Agreement for Argentina
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2
... Businesses Encouraged to Reduce Air Pollution, HARRISBURG, ... and its regional air quality partnerships have,forecast an ... in the,Berks/Lehigh, Liberty/Clairton, Philadelphia, Pittsburgh and Susquehanna,Valley regions., ... be code ORANGE for,ozone in the Berks/Lehigh Valley, ...
... brain are lost through disease or injury, neighboring cells begin ... the brain are able to produce new neurons. Patients with ... an area of the brain called the substantia nigra and ... these areas have not been well described because of limitations ...
... family reunion in Arkansas. The nurse and the research coordinator at The ... going West in search of the serum that binds this family. More ... ... Christine Demers and Areeba Sadiq set off for a family reunion in ...
... Program Encourages Kids to ,Eat Smart for a Great Start, ... ... ,Produce for Kids(R) (PFK), an organization that promotes the benefits of,healthy eating ... and tools that support the positive,development of the whole child - the ...
... N.J., Sept. 3 Teva,Pharmaceutical Industries Ltd. (Nasdaq: ... BRL ) announced today that, as expected, each ... referred to as a "second,request") from the U.S. ... acquisition of Barr. The parties have been cooperating ...
... 3 Z Trim Holdings,Inc. (Amex: ZTM ) issued ... September 3, 2008, To: Z Trim Shareholders, ... In this second installment of periodic updates intended to ... on the motives and,outcomes -- realized and anticipated -- behind ...
Cached Medicine News:Health News:Air Quality Action Day Forecast Thursday in All Regions 2Health News:New methods identify and manipulate 'newborn' cells in animal model of Parkinson's disease 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 2Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 3Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 4Health News:Feinstein Institute: Researching a Family Tree of Autoimmune Disorders 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 2Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 3Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 4Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 5Health News:Produce for Kids(R) and PBS KIDS(R) Partner for a Second Year with Nationwide School-Based Healthy Eating Campaign 6Health News:Teva and Barr Receive FTC Request for Additional Information 2Health News:Teva and Barr Receive FTC Request for Additional Information 3Health News:Teva and Barr Receive FTC Request for Additional Information 4Health News:Teva and Barr Receive FTC Request for Additional Information 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 2Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 3Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 4Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 5Health News:Z Trim Holdings, Inc. Releases Letter to Shareholders 6
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A low viscosity type of bone cement, intended for syringe or cement gun application....
Antibiotics (Gentamicin) loaded, low viscosity bone cement for syringe use with an average setting time of approx. 7-9 Min., 41.6g of powder and 16.4g of liquid....
Medicine Products: